Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H Boucher, Aimee Jackson, Rachel S Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hannah R Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J Mead, Steven Knapper, Joanne Ewing, Nauman M Butt, Manish Jain, Sebastian Francis, Fiona J Clark, Jason Coppell, Mary F McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W Drummond, Mallika Sekhar, Hesham ElDaly, Judy Hirst, Maike Paramor, E Joanna Baxter, Anna L Godfrey, Claire N Harrison, Simón Méndez-Ferrer
Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2V617F , CALRins5 or CALRdel52 peripheral blood allele burden ≥20% (EudraCT 2015-005497-38). 38 patients were recruited over 112w and 32 completed 24w-treatment...
November 25, 2023: Nature Communications